How many insider trades does FilingIQ track for SLXN?

FilingIQ tracks 27 Form 4 insider transactions for SLXN (Silexion Therapeutics Corp), covering filings from Feb 9, 2025 onwards. 14 of those were filed in the last 90 days.

Are SLXN insiders net buyers or net sellers?

Across the full Form 4 history for SLXN, 0 transactions (0%) were open-market purchases and 1 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SLXN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SLXN in?

Silexion Therapeutics Corp (SLXN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.44M.

SLXN insider trading

NasdaqCM Healthcare

Silexion Therapeutics Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 4%

Market cap

$4.44M

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Company website: silexion.com

SLXN insider activity at a glance

FilingIQ has scored 27 insider transactions for SLXN since Feb 9, 2025. The most recent filing in our index is dated Mar 26, 2026.

Across the full history, 0 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SLXN insider trades is 69.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SLXN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for SLXN?: FilingIQ tracks 27 Form 4 insider transactions for SLXN (Silexion Therapeutics Corp), covering filings from Feb 9, 2025 onwards. 14 of those were filed in the last 90 days.
Are SLXN insiders net buyers or net sellers?: Across the full Form 4 history for SLXN, 0 transactions (0%) were open-market purchases and 1 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SLXN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SLXN in?: Silexion Therapeutics Corp (SLXN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.44M.

Methodology & sources

Every SLXN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.